Table 3.
Incidence of Contrast‐Induced Nephropathy and In‐Hospital Clinical Outcomes by HV/W Quartiles
| Characteristics | HV/W Quartiles | P trend | |||
|---|---|---|---|---|---|
| Q1 (n=350) | Q2 (n=351) | Q3 (n=366) | Q4 (n=339) | ||
| Scr increase ≥0.5 mg/dL, n (%) | 5 (1.4) | 8 (2.3) | 20 (5.5) | 29 (8.6) | <0.001 |
| Scr increase ≥0.5 mg/dL or ≥25%, n (%) | 15 (4.3) | 23 (6.6) | 40 (10.9) | 51 (15.0) | <0.001 |
| Scr increase ≥0.3 mg/dL, n (%) | 10 (2.9) | 16 (4.7) | 31 (8.7) | 49 (14.7) | <0.001 |
| Scr increase ≥0.3 mg/dL or ≥50%, n (%) | 10 (2.9) | 16 (4.7) | 31 (8.7) | 49 (14.7) | <0.001 |
| Stay, days, median (P25–P75) | 4 (2–6) | 5 (3–7) | 5 (3–8) | 6 (4–9) | <0.001 |
| Cost, USD, median (P25–P75) | 8314 (39.7–67.7) | 8634 (40.8–73.9) | 9274 (44.6–80.8) | 10 073 (45.2–88.3) | <0.001 |
| Acute heart failure, n (%) | 1 (0.29) | 8 (2.28) | 10 (2.73) | 17 (5.01) | 0.001 |
| Death, n (%) | 1 (0.3) | 2 (0.6) | 8 (2.2) | 15 (4.4) | <0.001 |
| Require RRT, n (%) | 1 (0.3) | 2 (0.6) | 10 (2.9) | 14 (1.0) | <0.001 |
HV/W indicates ratio of hydration volume to body weight; Q, quartile; RRT, renal replacement therapy; Scr, serum creatinine; USD, US dollars.